Jun 2, 2025, 09:20

Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)

Supports advanced pre-clinical development of nanotechnology-based cancer diagnostics and therapeutics (nanoparticles ≤ 300 nm or nano-devices) aimed at high-impact clinical objectives. Projects must mature interventions to a stage suitable for GMP/GLP readiness and subsequent participation in NCI’s NExT or other translational programs. Emphasis is on clinically relevant combination therapies, immunotherapies, or imaging/diagnostics that outperform current standards.

Eligibility

Eligible Organizations (U.S. only):
- Higher education institutions (public/private)
- Nonprofits (with or without 501(c)(3))
- For-profit organizations (including small businesses)
- Local/state/tribal governments, faith-based/regional organizations
- ** Foreign organizations and non-U.S. components are not eligible**; however, foreign subcontracts (“foreign components”) are allowed.
Investigators:
- PD(s)/PI(s) must have eRA Commons accounts. Multidisciplinary leadership—including at least one investigator with pertinent clinical expertise—is required.
Project Type:
- R01 Research Project Grant (pre-clinical, no clinical trials; in vitro human specimen studies permitted).

Funding

Mechanism: R01 (clinical trial not allowed)
Budget:
- ≤ $475,000 direct costs per year
- Must justify budget relative to advanced pre-clinical scope
Project Period: Up to 4 years
Number of Awards: Contingent on NCI appropriations and merit

Key Dates

Posted: December 16, 2024
Open (Earliest Submission): April 19, 2025
Application Due Dates (5:00 PM local time):
- May 19, 2025 (new/renewal/resubmission/revision) → Review Nov 2025 → Council Jan 2026 → Start Apr 2026
- November 17, 2025 → Review Mar 2026 → Council May 2026 → Start Jul 2026
- May 18, 2026 → Review Nov 2026 → Council Jan 2027 → Start Apr 2027
- November 16, 2026 → Review Mar 2027 → Council May 2027 → Start Jul 2027
- May 17, 2027 → Review Nov 2027 → Council Jan 2028 → Start Apr 2028
- November 15, 2027 → Review Mar 2028 → Council May 2028 → Start Jul 2028
Expiration: November 16, 2027

Contacts

Scientific/Research Contacts (NCI):
- Piotr Grodzinski, Ph.D.
  
  Phone: 240-781-3305 | Email: [email protected]
- Yicong Wu, Ph.D.
  
  Phone: 240-276-5634 | Email: [email protected]
Peer Review Contact (CSR):
- Mark G. Caprara, Ph.D.
  
  Phone: 301-827-3076 | Email: [email protected]
Grants Management Contact (NCI):
- Shane Woodward
  
  Phone: 240-276-6303 | Email: [email protected]